Stock Ratings / Health Care / HUMA / dividends

MOLN (50) CMPX (46) CHRS (36) ARMP (43) ⌘ Pro Terminal →

Humacyte Inc. (HUMA) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.47 -0.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.47

Humacyte Inc. (HUMA) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $130.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HUMA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HUMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Humacyte Inc. (NASDAQ: HUMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.47 (-0.06% 1D, market cap $130.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HUMA ranks #812 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HUMA compare to MOLN and CMPX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HUMA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MOLN (Molecular Partners AG) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $132.4M) and CMPX (Compass Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -34.6%, cap $136.2M). Among the 5-stock peer group, HUMA leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HUMA?

▼

Per HUMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818382), Humacyte Inc. generated $2.0M in revenue, -$40.8M in net income, and -$105.9M in free cash flow against $116.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.47 (-0.20%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HUMA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY HUMA SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.39+2.6% Next Q

Q2 (-2Q)

Grade E$0.40+0% Next Q

Q3 (-1Q)

Grade E$0.40+17.5% Next Q

Current

Grade E$0.47-9.4% Hist 90D α

Trajectory: E (23) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HUMA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HUMA currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.52) and Max Pain ($0.49) forces dealer call-delta covering toward $1.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HUMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HUMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HUMA)

✓Walkthrough of HUMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HUMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.46%⚡ TESTING RESISTANCE

2026-11-02O $0.47H $0.47L $0.47C $0.47VOL 3.70M

RES: $0.50SUP: $0.24SMA50: $0.52SMA200: $0.80

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HUMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HUMA Butterfly Map → + Track HUMA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HUMA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HUMA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HUMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HUMA)

Health Care Rank #812 of 1016 ⚔️ MOLN vs HUMA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HUMA vs. MOLN, CMPX, CHRS, ARMP)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Humacyte Inc. (HUMA) ranks #812 by composite RQD confidence (31/100, grade E) and #628 by equity capitalization ($130.5M). Within this direct 5-issuer industry benchmark cohort, HUMA leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. MOLN currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with HUMA at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HUMA ACTIVE Humacyte Inc.	E	31/100	—	-30.0%	-35.0%	-0.06%	$130.5M	Benchmark Subject
MOLN Molecular Partners AG	D	50/100	—	—	—	-4.88%	$132.4M	/moln-vs-huma →
CMPX Compass Therapeutics Inc.	D	46/100	—	—	-34.6%	-0.54%	$136.2M	/cmpx-vs-huma →
CHRS Coherus Oncology Inc.	D-	36/100	—	—	-35.0%	-22.55%	$138.8M	/chrs-vs-huma →
ARMP Armata Pharmaceuticals Inc.	D-	43/100	—	—	-35.0%	-1.22%	$120.8M	/armp-vs-huma →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818382

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Humacyte Inc. (HUMA) reported GAAP revenue of $2.0M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$40.8M, operating cash flow of -$105.0M, and free cash flow of -$105.9M (-6.3% YoY). On the balance sheet, HUMA closed FY2025 with $116.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.0M	-$40.8M	-$105.0M	-$105.9M	$116.4M	—
FY2024 (FY)	2024-12-31	$0	-$148.7M	-$98.1M	-$99.7M	$137.9M	—
FY2023 (FY)	2023-12-31	$0	-$110.8M	-$73.3M	-$73.3M	—	—

3. HUMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HUMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HUMA compare to MOLN and CMPX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HUMA?

Where is HUMA trading relative to its 50-day, 200-day, and 52-week technical levels?

HUMA last traded at $0.47 (-0.06% on volume of 3,704,487 shares), positioning the stock -9.62% below its 50-day simple moving average ($0.52) and -41.25% below its 200-day simple moving average ($0.80). Across its 52-week range of $0.34 to $1.68, HUMA sits at the 9.7% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.53).

HUMA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does HUMA pay a dividend and is it safe?

Humacyte Inc. (HUMA) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: HUMA RQD Cockpit HUMA 12M Forecast HUMA Earnings & Move HUMA Dividends & DRIP HUMA Insiders & 13F HUMA Whale Options HUMA Profit Sankey HUMA News & Why